Any current/future new fundraising through debt or equity?

For FY26, Neuland Laboratories had a net increase in long-term borrowings of INR 60.9 crores. Closing long-term borrowings at the end of Q4FY26 stood at INR 197 crores. The company maintains a strong financial position with negative net debt of INR 157 crores, supported by cash balances of INR 353 crores. Capex cash outflow for FY26 was INR 397.1 crores, indicating ongoing investments funded through internal accruals and borrowings. No specific mention of any new fundraising plans through debt or equity was made during the call. Management emphasized disciplined, phased capex aligned with stra

Any current/future capex/capital investment/strategic investment?

Neuland is in a phase of longer capital deployment cycles focused on long-term growth rather than tactical investments (Page 11). Capex outflow for FY26 was INR 397.1 crores, executed with discipline aligned with strategic priorities emphasizing returns and capability building (Page 4). Investments include building a large-scale peptide commercial facility to expand capabilities in peptide APIs and fragments (Page 5). New R&D center for supporting complex programs, enhancing scientific depth, collaboration, and scale from early development to commercialization (Page 5). Capital allocation mind

Future growth expectations in sales/revenue/volumes?

Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management. FY26 revenue reached INR 2,000 crores, up from INR 1,500+ crores in FY24, reflecting meaningful growth after a volatile FY25. Growth is expected to remain lumpy and volatile in the short to medium term due to the nature of the business and newer high-value molecules. Long-term growth is anchored by commercial and near-commercial molecules, with a strong pipeline and increasing engagement with big pharma. Investments in large-scale peptide commercial facilities and an upgraded R&D cen

Future growth expectations in earnings/operating earnings/profits/EPS?

Neuland targets an 18% to 20% CAGR over a 5-year horizon, described as aspirational rather than linear growth (Saharsh Davuluri, page 15). FY26 growth marked meaningful progress with revenue reaching INR 2,000 crores from INR 1,500+ crores in FY24, despite volatility in interim periods (page 15). Margins are expected to be stable with a conservative budgeting approach; H2 margins may be a better indicator than Q4 alone (page 13). EBITDA margin for FY26 was 29.4%, up from 22.9% in FY25, reflecting improved operating leverage (page 2). Profit after tax for FY26 was INR 363.1 crores (EPS INR 283.

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the exact current or expected order book or pending orders in quantitative terms. Management indicates "visibility for projects" especially for the new peptide facility expected to be operational by July, suggesting a healthy pipeline. Early-stage projects for the peptide facility are near commercial, with project visibility but not yet firm contracts. The business development focus is on attracting high-quality, sustainable growth opportunities and larger projects. CDMO business discussions emphasize ongoing engagements and contracted relationships b

IN US

Sale is live|00:00:00left today

Neuland Laboratories LtdQ1 FY26Pharmaceuticals & Biotechnology

Neuland Laboratories Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹17,961P/E: 58.5Market Cap: ₹21.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management.
→FY26 revenue reached INR 2,000 crores, up from INR 1,500+ crores in FY24, reflecting meaningful growth after a volatile FY25.
→Growth is expected to remain lumpy and volatile in the short to medium term due to the nature of the business and newer high-value molecules.
→Long-term growth is anchored by commercial and near-commercial molecules, with a strong pipeline and increasing engagement with big pharma.
→Investments in large-scale peptide commercial facilities and an upgraded R&D center aim to expand capacity and technical capabilities, supporting sustainable growth.
→The company focuses on selective, high-quality growth opportunities even if it means short-term lumpiness.
→Management advises evaluating growth over multiple quarters (10-12 quarters) rather than quarterly precision due to inherent variability.

Margin guidance

Category 4

→Neuland targets an 18% to 20% CAGR over a 5-year horizon, described as aspirational rather than linear growth (Saharsh Davuluri, page 15).
→FY26 growth marked meaningful progress with revenue reaching INR 2,000 crores from INR 1,500+ crores in FY24, despite volatility in interim periods (page 15).
→Margins are expected to be stable with a conservative budgeting approach; H2 margins may be a better indicator than Q4 alone (page 13).
→EBITDA margin for FY26 was 29.4%, up from 22.9% in FY25, reflecting improved operating leverage (page 2).
→Profit after tax for FY26 was INR 363.1 crores (EPS INR 283.01), showing strong profitability growth (page 2).
→Management emphasizes longer-term growth focus, acknowledging lumpiness in quarterly earnings but expects a clear upward trend over multiple quarters (page 6).
→Investments in peptide commercial facilities and R&D strengthen the growth engine, supporting sustainable high-quality growth (page 6).

3 more insights locked — sign up free to unlock

Fundraise plans

→For FY26, Neuland Laboratories had a net increase in long-term borrowings of INR 60.9 crores.
→Closing long-term borrowings at the end of Q4FY26 stood at INR 197 crores.
→The company maintains a strong financial position with negative net debt of INR 157 crores, supported by cash balances of INR 353 crores.
→Capex cash outflow for FY26 was INR 397.1 crores, indicating ongoing investments funded through internal accruals and borrowings.
→No specific mention of any new fundraising plans through debt or equity was made during the call.
→Management emphasized disciplined, phased capex aligned with strategic priorities and maintaining financial flexibility.
→Focus remains on preserving liquidity to support growth investments without explicitly announcing fresh fundraising.

Order book

→The transcript does not explicitly mention the exact current or expected order book or pending orders in quantitative terms.
→Management indicates "visibility for projects" especially for the new peptide facility expected to be operational by July, suggesting a healthy pipeline.
→Early-stage projects for the peptide facility are near commercial, with project visibility but not yet firm contracts.
→The business development focus is on attracting high-quality, sustainable growth opportunities and larger projects.
→CDMO business discussions emphasize ongoing engagements and contracted relationships but maintain confidentiality regarding specific molecules and orders.
→Overall, the company shows confidence in its pipeline and order visibility, particularly from commercial and near-commercial molecules, supporting growth in the next 2-3 years.

Capex plans

Yes

→Neuland is in a phase of longer capital deployment cycles focused on long-term growth rather than tactical investments (Page 11).
→Capex outflow for FY26 was INR 397.1 crores, executed with discipline aligned with strategic priorities emphasizing returns and capability building (Page 4).
→Investments include building a large-scale peptide commercial facility to expand capabilities in peptide APIs and fragments (Page 5).
→New R&D center for supporting complex programs, enhancing scientific depth, collaboration, and scale from early development to commercialization (Page 5).
→Capital allocation mindset is evolving to support larger annual capex (hundreds to INR 1,000 crores) for scaling production and engaging big pharma clients (Page 11).
→Focus on execution discipline to ensure capex translates into clear milestones and business outcomes (Page 4).
→Capital investment also supports strengthening the CDMO business and readiness for new client engagement (Page 15).

How does Neuland Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Neuland Laboratories Ltd

Rev 3Mar 4

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Neuland Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio